Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Theralase Technologies Inc.
Bullboard Posts
User Avatar Image
(5)
•••
Post by GRAMPS1996on Jun 29, 2018 4:31pm
320 Views
Post# 28253960

Interesting: Kensington Capital Partners

Interesting: Kensington Capital Partners

Kristina Hachey, Theralase Technologies Inc: Profile ...

https://www.bloomberg.com/profiles/people/7388594-kristina-hachey

Kristina Hachey is Chief Financial Officer at Theralase Technologies Inc. See Kristina Hachey's compensation, ... Executive Kensington Capital Partners Ltd, PRESENT;

  • Works For: Theralase Technologies Inc
  • Title: Chief Financial Officer
  • Occupation: Chief Financial Officer
  • Location: 29 Gervais Drive


Ottawa names five winning funds to receive $350-million in latest venture-capital program

Date Posted: June 27, 2018

The Trudeau government has selected five fund-of-fund managers to make good on its pledge to continue supporting Canada’s venture-capital industry. Ottawa is going mostly with familiar names for its Venture Capital Catalyst Initiative (VCCI), first announced in the 2017 budget after intense lobbying by Canadian venture capitalists. Four of the five managers chosen to disburse $350-million on the government’s behalf to venture-capital firms – that in turn invest directly in startups – were the same quartet chosen by the previous Conservative government for a similar initiative: Northleaf Capital Partners and Kensington Capital Partners of Toronto; Teralys Capital of Montreal; and Boston-based HarbourVest Partners LLC.

Read More »


Bullboard Posts
Dealroom for high-potential pre-IPO opportunities